Akebia Therapeutics granted three newly hired employees options to purchase an aggregate of 125,600 shares of common stock on June 30, 2026, as an inducement material to their employment. The options have an exercise price of $1.14 per share, equal to the closing price on the grant date, and vest over four years with 25% after one year and the remainder quarterly thereafter. Each option has a 10-year term and was granted under Nasdaq Listing Rule 5635(c)(4).
Akebia TherGrant of inducement stock options to new employees; no direct impact on business performance.